SARS COV-2 and its related disease COVID 19 has led to a major global pandemic and in absence of no known effective therapeutic agents against it, virus is having a free run. Sequence analyses, homology modelling and docking have suggested potential drugs which can be used against this virus. Sofosubivir is a direct-acting antiviral agent with NS5B RNA-dependent RNA polymerase (RdRp) inhibitory activity used in management of Hepatitis-C infection. This drug has potential role in managing this viral disease. Safety and efficacy of this drug is already established in patients of Hepatitis-C where it is given for long periods of time. Favourable pharmacokinetic profile of this drug also favors it use in this infection. This report summarises information available which can be explored further in clinical trials.